Title:DHA and EPA in Sickle Cell Disease Favor Clinical Improvement and Contribute to Better Quality of Life: A Qualitative Systematic Review
Volume: 16
Author(s): Jamille da Conceicao Souza., Ana Paula Azevêdo Macêdo, Mariane dos Santos Gonçalves, Adriano de Souza Santos Monteiro, Cynara Gomes Barbosa, Fábio David Couto and Ricardo David Couto*
Affiliation:
- Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Bahia, Brazil
Keywords:
Sickle cell disease, omega-3 fatty acids, n-3 PUFA, HbS disease, welfare, hemoglobinopathies.
Abstract: Background: Sickle cell disease is a severe genetic disorder, and searching for therapeutic
strategies is indispensable for prolonged and improved life for people affected by this condition.
Objective: This qualitative systematic review aimed to highlight the therapeutic potential of omega-
3 (n-3) in people with sickle cell disease.
Methods: The search was performed by combining sickle cell disease and n-3 descriptors in DeCS/
MeSH databases, including Scopus, PubMed, ScienceDirect, Web of Science, and Virtual
Health Library. The risk of bias assessment in the primary studies was performed using the
Cochrane risk of bias tool for randomized controlled trials. The evidence quality was evaluated using
the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool.
Results: From the 187 records identified, seven were selected for data collection. Based on the evidence,
n-3 supplementation contributes to lower activation of pro-inflammatory biomarkers, improves
the concentration of docosahexaenoic and eicosapentaenoic acids in the erythrocyte membrane,
provides better hemostatic response, and helps in vaso-occlusive crisis, pain episodes, and
hospitalization reduction.
Conclusion: The findings suggest that n-3 adjuvant therapy favors the clinical and general aspects
of people with sickle cell disease.
